𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Investigating the neuroprotective mechanism of action of a CDK5 inhibitor by phosphoproteome analysis

✍ Scribed by Frank Gillardon; André Schrattenholz; Bernd Sommer


Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
218 KB
Volume
95
Category
Article
ISSN
0730-2312

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Small molecule inhibitors of cyclin‐dependent kinase 5 (CDK5) protect neurons from cell death following various insults. To elucidate the cellular mechanism of action we investigated changes in protein phosphorylation in cultured rat cerebellar granule neurons after administration of the CDK5 inhibitor Indolinone A. By immunoblot analysis we detected enhanced phosphorylation of the extracellular signal‐regulated kinase1/2 (ERK1/2) and the Jun N‐terminal kinase (JNK) substrate c‐Jun. Co‐administration of U0126, an inhibitor of ERK1/2, or SP600125, an inhibitor of JNK, blocked phosphorylation of ERK1/2 or c‐Jun, but did not affect neuroprotection by the CDK5 inhibitor. By metal affinity chromatography, two‐dimensional (2D) gel electrophoresis, and MALDI‐TOF mass spectrometry we identified several phosphoproteins that accumulated in neurons treated with Indolinone A. Among them were proteins involved in neurotransmitter release, which is consistent with a physiological function of CDK5 in synaptic signaling. Moreover, we identified proteins acting in energy metabolism, protein folding, and oxidative stress response. Similar findings have been reported in yeast following inhibition of Pho85 kinase, which is homologous to mammalian CDK5 and acts in environmental stress signaling. These results suggest that inhibition of CDK5 activates stress responsive proteins that may protect neurons against subsequent injurious stimuli. © 2005 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


Studies on the mechanism of action of 5-
✍ T. A. Connors; D. H. Melzack 📂 Article 📅 1971 🏛 John Wiley and Sons 🌐 French ⚖ 470 KB

## Abstract CB 1954, a monofunctional alkylating agent, has exceptional activity against the Walker carcinoma yet is inactive against a large number of other animal tumours. A line of the Walker tumour with acquired resistance to CB 1954 was cross‐resistant to Melphalan, implying a common mechanism